New HIV drug Biktarvy sales of ₩20 billion in one year

Gilead maintains leadership in the HIV treatment market amid rapid growth in Biktarvy

Triumeq byGSK, ₩15.4 billion in the first half,

It is confirmed that Gilead Science's new HIV treatment, Biktarvy, made close to ₩20 billion in a year after it entered the market in earnest.

 

According to the analysis, Gilead is maintaining the leadership in the HIV treatment market due to the rapid growth of Biktarvy.

 

◆Biktarvy, sales of ₩14.4 billion in the first half of this year, Cumulative ₩19.4 billion

Biktarvy

According to IQVIA, a drug market research institute on the 31st, the sales of Biktarvy in the first half of the year are estimated at ₩14.4 billion.

 

Biktarvy is a combination　HIV treatment　which consists of Bictegravir, Emtricitabine, and Tenofovir alafenamide.

 

After receiving approval from the MFDS in January of last year, it entered the market in earnest while receiving reimbursement in July of the same year.

 

Yuhan is in charge of marketing in the domestic market.

 

For the first half year from July to December, Biktarvy's sales amounted to ₩5 billion.

 

Adding ₩14.4 billion in sales until the first half of this year is ₩19.4 billion.

 

In less than a year of launch, it has produced close to ₩20 billion in sales.

 

Quarterly sales of Biktarvy by Gilead Sciences and major HIV treatments (unit: ₩billion, data: IQVIA)

Compared to existing treatments, the efficacy and safety are improved, and the rate of onset of resistance is low.

 

Bictegravir is an active ingredient that is evaluated as a strong second-generation integrative enzyme inhibitor and has high resistance.

 

Tenofovir alafenamide is also a second-generation Tenofovir, changing its base to significantly lower its toxic effects on kidneys and bones, the company explains.

 

It can be taken with/without food, and the size of the pill is smaller than that of existing treatments.

 

◆Gilead maintains market leadership amid rapid growth in Biktarvy With Biktarvy's rapid growth, Gilead remains a leader in the HIV treatment market.

 

In the domestic market, Gilead, GSK, MSD, Janssen, AbbVie, and BMS are competing for HIV treatment.

 

Among them, Gilead and GSK are known to occupy about 90% of the market.

 

In the case of Gilead, the total sales of five treatments (Genvoya, Descovy, Truvada, Stribild) including Biktarvy in the first half of this year were ₩27.7 billion, up 19% from ₩22.3 billion in the first half of last year.

 

The sales of other treatments, excluding Biktarvy, declined, but Biktarvy offset this.

 

It is explained that the prescriptions for Genvoya are being replaced by Biktarvy.

 

GSK's Triumeq posted sales of ₩15.4 billion.

 

It increased by 16% compared to ₩13.3 billion in the first half of last year.

 

GSK's another HIV treatment Tivicay increased 14% from ₩2.2 billion to ₩2.5 billion over the same period, and Kivexa decreased 23% from ₩1.7 billion to ₩1.3 billion.

 

GSK plans to pursue Gilead with a new HIV treatment, Dovato.

 

After being approved in Korea in March this year, Dovato entered the market in earnest after being listed as a health insurance benefit in June.

 

Dovato is a single tablet that is a mixture of two ingredients: Dolutegravir and Lamivudine.

 

Semiannual sales of major HIV treatments (unit: ₩100 million, data:IQVIA)

In addition, MSD's Isentress recorded sales of ₩2.8 billion in the first half of this year, Prezcobix by Janssen of ₩1.3 billion, AbbVie's Kaletra of ₩1.3 billion, and BMS' Evotaz of ₩500 million.

 

In the case of AbbVie’s Kaletra, it was mentioned as one of the potential treatments at the beginning of the COVID-19 incident in the first half of this year.